<!DOCTYPE html>
<html prefix='og: http://ogp.me/ns#'>
<head>
<link href='../favicon.png' rel='icon' type='image/png'>
<link href='../assets/apple-touch-icon.png' rel='apple-touch-icon' sizes='72x72' type='image/png'>
<link href='trials.html' rel='canonical'>
<meta content='text/html;charset=utf-8' http-equiv='Content-Type'>
<meta content='IE=edge,chrome=1' http-equiv='X-UA-Compatible'>
<script type="text/javascript">window.NREUM||(NREUM={});NREUM.info={"beacon":"beacon-6.newrelic.com","errorBeacon":"bam.nr-data.net","licenseKey":"df7d6b7270","applicationID":"3316025","transactionName":"cl5cF0cLWlsDEEsHWF9FVw1BS0JFDwMIO0dQVlc=","queueTime":0,"applicationTime":220,"ttGuid":"","agentToken":null,"agent":"js-agent.newrelic.com/nr-515.min.js"}</script>
<script type="text/javascript">window.NREUM||(NREUM={}),__nr_require=function(n,t,e){function r(e){if(!t[e]){var o=t[e]={exports:{}};n[e][0].call(o.exports,function(t){var o=n[e][1][t];return r(o?o:t)},o,o.exports)}return t[e].exports}if("function"==typeof __nr_require)return __nr_require;for(var o=0;o<e.length;o++)r(e[o]);return r}({QJf3ax:[function(n,t){function e(n){function t(t,e,a){n&&n(t,e,a),a||(a={});for(var u=c(t),f=u.length,s=i(a,o,r),p=0;f>p;p++)u[p].apply(s,e);return s}function a(n,t){f[n]=c(n).concat(t)}function c(n){return f[n]||[]}function u(){return e(t)}var f={};return{on:a,emit:t,create:u,listeners:c,_events:f}}function r(){return{}}var o="nr@context",i=n("gos");t.exports=e()},{gos:"7eSDFh"}],ee:[function(n,t){t.exports=n("QJf3ax")},{}],gos:[function(n,t){t.exports=n("7eSDFh")},{}],"7eSDFh":[function(n,t){function e(n,t,e){if(r.call(n,t))return n[t];var o=e();if(Object.defineProperty&&Object.keys)try{return Object.defineProperty(n,t,{value:o,writable:!0,enumerable:!1}),o}catch(i){}return n[t]=o,o}var r=Object.prototype.hasOwnProperty;t.exports=e},{}],D5DuLP:[function(n,t){function e(n,t,e){return r.listeners(n).length?r.emit(n,t,e):(o[n]||(o[n]=[]),void o[n].push(t))}var r=n("ee").create(),o={};t.exports=e,e.ee=r,r.q=o},{ee:"QJf3ax"}],handle:[function(n,t){t.exports=n("D5DuLP")},{}],XL7HBI:[function(n,t){function e(n){var t=typeof n;return!n||"object"!==t&&"function"!==t?-1:n===window?0:i(n,o,function(){return r++})}var r=1,o="nr@id",i=n("gos");t.exports=e},{gos:"7eSDFh"}],id:[function(n,t){t.exports=n("XL7HBI")},{}],loader:[function(n,t){t.exports=n("G9z0Bl")},{}],G9z0Bl:[function(n,t){function e(){var n=v.info=NREUM.info;if(n&&n.licenseKey&&n.applicationID&&f&&f.body){c(d,function(t,e){t in n||(n[t]=e)}),v.proto="https"===l.split(":")[0]||n.sslForHttp?"https://":"http://",a("mark",["onload",i()]);var t=f.createElement("script");t.src=v.proto+n.agent,f.body.appendChild(t)}}function r(){"complete"===f.readyState&&o()}function o(){a("mark",["domContent",i()])}function i(){return(new Date).getTime()}var a=n("handle"),c=n(1),u=window,f=u.document,s="addEventListener",p="attachEvent",l=(""+location).split("?")[0],d={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net",agent:"js-agent.newrelic.com/nr-515.min.js"},v=t.exports={offset:i(),origin:l,features:{}};f[s]?(f[s]("DOMContentLoaded",o,!1),u[s]("load",e,!1)):(f[p]("onreadystatechange",r),u[p]("onload",e)),a("mark",["firstbyte",i()])},{1:11,handle:"D5DuLP"}],11:[function(n,t){function e(n,t){var e=[],o="",i=0;for(o in n)r.call(n,o)&&(e[i]=t(o,n[o]),i+=1);return e}var r=Object.prototype.hasOwnProperty;t.exports=e},{}]},{},["G9z0Bl"]);</script>
<meta content='ycLJxifWV5TMCaeBV4zy1XzXAlxSn13YlTqZjZ4_GeQ' name='google-site-verification'>
<!-- / OG and Twitter Card meta data tags -->
<meta content="Clinical Trials for Cystic Fibrosis" property="og:description" />
<meta content="Clinical Trials for Cystic Fibrosis" property="twitter:description" />
<meta content="Clinical Trials for Cystic Fibrosis" property="og:title" />
<meta content="Clinical Trials for Cystic Fibrosis" property="twitter:title" />
<meta content="https://www.smartpatients.com/cystic-fibrosis/trials" property="og:url" />
<meta content="https://www.smartpatients.com/cystic-fibrosis/trials" property="twitter:url" />
<meta content="article" property="og:type" />
<meta content="article" property="twitter:type" />
<meta content="https://www.smartpatients.com/smart-patients-logo-200.png" property="og:image" />
<meta content="summary" property="twitter:card" />
<meta content="@smart_patients" property="twitter:site" />
<meta content="https://www.smartpatients.com/smart-patients-logo-200.png" property="twitter:image" />
<script>window.gon = {};gon.browser={"os":null,"platform":null,"browser":"SiteSucker","version":""};gon.selection=null;gon.privileges=[];</script>
<meta content="authenticity_token" name="csrf-param" />
<meta content="anHdzK0RV47A1fm+Cc5YWchDmz7Dd1CW3v8C5VSfjds=" name="csrf-token" />
<title>Clinical Trials for Cystic Fibrosis | Smart Patients</title>
<!--[if lt IE 10]>
<script src='https://html5shim.googlecode.com/svn/trunk/html5.js'></script>
<![endif]-->
<link href="../assets/application-d023587940a25f1311fac7be224dde01.css" media="all" rel="stylesheet" type="text/css" />
<link href="../assets/print/print-791dc2f04757964770191d5c923539c6.css" media="print" rel="stylesheet" type="text/css" />

<!--[if lt IE 10]>
<link href="/assets/ie/ie-fb3a9d11af866d1ad554b557627df8f6.css" media="all" rel="stylesheet" type="text/css" />
<![endif]-->
<!--[if lt IE 9]>
<link href="/assets/ie/ie8-b1f4d1991397313b50b84b7d76d6ba05.css" media="all" rel="stylesheet" type="text/css" />
<![endif]-->
<link href="https://fonts.googleapis.com/css?family=Handlee%7CBitter:400,700" rel="stylesheet" type="text/css" />

</head>

<body class='not-logged-in'>
<script id='tag_template' type='text/x-handlebars-template'>
<p>
{{{description}}}
</p>
<p class='status_{{tag_name}}'></p>
<p class='tag_link'>
<img alt="Icon_favorite_selected" src="/assets/icon_favorite_selected-37a484115fc7df83408fabd97664140b.png" />
{{{follow_link}}}
</p>
<img alt="Spinner" class="spinner hidden" src="/assets/spinner-3f3b3866a7fa212b261a33db16ecbaf5.gif" />
<div class='topic-count'>
<a href='{{tag_path}}'>
{{{count}}}
</a>
</div>
</script>

<script id='interest_template' type='text/x-handlebars-template'>
<li class='interest' data-interest-id='{{id}}'>
<div class='outer'>
<div class='inner'>
{{{url}}}
{{{remove_link}}}
</div>
</div>
</li>
</script>

<script id='alert_template' type='text/x-handlebars-template'>
<div class='alert {{class}}'>
<button aria-hidden='true' class='close' data-dismiss='alert' type='button'>
x
</button>
<p>
{{message}}
</p>
</div>
</script>

<script id='alert_template_html' type='text/x-handlebars-template'>
<div class='alert {{class}}'>
<button aria-hidden='true' class='close' data-dismiss='alert' type='button'>
x
</button>
<p>
{{{message}}}
</p>
</div>
</script>

<script id='profile_popup_template' type='text/x-handlebars-template'><pre class='profile_popup'>{{ profile }}</pre><div class='instructions'>
{{ instructions }}
</div>
</script>

<script id='survey_rating_results_template' type='text/x-handlebars-template'>
<div class='rating-result'>
<div>
{{message}}
</div>
<div>
Your rating: {{user_rating}}
</div>
<div>
Average: {{average}}
</div>
<div>
Total # of votes: {{count}}
</div>
</div>
</script>

<script id='target_details_template' type='text/x-handlebars-template'>
<p>
{{name}} <span class="pill {{node_type}}">{{node_type}}</span>
<ul>
{{#each neighbors}}
<li>
{{this.name}} <span class="pill {{this.node_type}}">{{this.node_type}}</span>
</li>
{{/each}}
</ul>
</p>
</script>

<script id='trial_contact_message' type='text/x-handlebars-template'>
I'm interested in "{{{brief_title}}}"
Trial ID: {{trial_id}}
{{institution}}
{{address}}
Thank you in advance for contacting me to discuss this trial.
</script>

<script id='featured_quote_template' type='text/x-handlebars-template'>
<div class='testimonial quoted-snippet'>
{{trimString quote 250}}
</div>
{{#if attribution}}
<div class='signed'>
– {{attribution}}
</div>
{{/if}}
</script>


<div class='container'>
<div class='navbar'>
<div class='navbar-inner'>
<div class='clearfix'>
<div class='row'>
<a href="../index.html" class="brand"><img alt="Smart-patients-logo-350" height="69" src="../assets/smart-patients-logo-350-bb0285894b87daf2798d6c0a81d0c51b.png" style="height: 69px" width="350" /></a>
<ul class='nav'>
</ul>

</div>
</div>
</div>
</div>
</div>

<div class='container' data-title='Clinical Trials for Cystic Fibrosis | Smart Patients' id='page'>
<div class='row'>
<div class='span2'></div>
<div class='span10 divider main'>
<div class='row'>
<div class='span7 messages'>

</div>
</div>
</div>
</div>
<div class='row'>
<div class='span12 divider main'>
<div class='row'>
<div class='span9 right-divider'>
<script id='trial_popover_template' type='text/x-handlebars-template'>
<ul>
{{ds}}
{{#each trials}}
<li>
{{#if this.link}}
<a class='trial_widget_links' data-intervention='{{../../../intervention}}' data-trial-id='{{this.id}}' href='{{this.link}}' target='_blank'>
{{this.id}}
{{#if this.text}}
({{this.text}})
{{/if}}
</a>
{{else}}
{{#if ../../source}}
<a href='/clinical-trials/{{this.id}}?source={{../../source}}' target='_blank'></a>
{{else}}
<a class='trial_widget_links' data-intervention='{{../../../intervention}}' data-trial-id='{{this.id}}' href='/clinical-trials/{{this.id}}' target='_blank'>
{{/if}}
{{this.id}}
{{#if this.text}}
({{this.text}})
{{/if}}
</a>
{{/if}}
<p>
{{trimString this.title 120}}
</p>
</li>
{{/each}}
</ul>
</script>




<div id='content-page'>
<div class='content-title'>
<h1>Clinical Trials for Cystic Fibrosis</h1>
</div>
<div class='content-main'>
<p>
Researchers around the world are working to develop new drugs for the treatment of cystic fibrosis. These new treatments must go through a rigorous trial process, testing their safety and efficacy, before they are made available to the people who need them. Patients play a critical role in the development of new treatments through their participation in these clinical trials.
</p>
<p>
Below are ongoing clinical trials for cystic fibrosis that have been organized into various categories by the
<a href='http://www.cff.org/research/DrugDevelopmentPipeline/' target='_blank'>Cystic Fibrosis Foundation</a>.
</p>
<div class='trial-container'>
<table id='trial-widget'>
<tr>
<th>
<div class='condition_name'>

</div>
</th>
<th>
<div class='big'>
3
</div>
<div class='th_label'>
phase 1
</div>
</th>
<th>
<div class='big'>
19
</div>
<div class='th_label'>
phase 2
</div>
</th>
<th>
<div class='big'>
26
</div>
<div class='th_label'>
phase 3
</div>
</th>
<th>
<div class='big'>
9
</div>
<div class='th_label'>
other*
</div>
</th>
<th>
<div class='big'>
57
</div>
<div class='th_label'>total</div>
</th>
</tr>
<tr class="subheader_0"><td colspan="6">CFTR Modulation</td></tr><tr><td><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Kalydeco</span><em class="manufacturer"></em><td data-content-name="cystic-fibrosis" data-intervention="Kalydeco" data-phase="phase1" data-placement="bottom" data-popup-id="popover-div" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="cystic-fibrosis" data-intervention="Kalydeco" data-phase="phase2" data-placement="bottom" data-popup-id="popover-div" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00457821&quot;,&quot;title&quot;:&quot;Safety Study of Ivacaftor in Subjects With Cystic Fibrosis&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00953706&quot;,&quot;title&quot;:&quot;Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Homozygous for the F508del-CFTR Mutation&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01262352&quot;,&quot;title&quot;:&quot;Study of the Effect of Ivacaftor on Lung Clearance Index in Subjects With Cystic Fibrosis and the G551D Mutation&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">3</td><td class="on phases" data-content-name="cystic-fibrosis" data-intervention="Kalydeco" data-phase="phase3" data-placement="bottom" data-popup-id="popover-div" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01705145&quot;,&quot;title&quot;:&quot;Study of Ivacaftor in Cystic Fibrosis Subjects 2 Through 5 Years of Age With a CTFR Gating Mutation&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01707290&quot;,&quot;title&quot;:&quot;Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00909532&quot;,&quot;title&quot;:&quot;Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older With the G551D Mutation&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00909727&quot;,&quot;title&quot;:&quot;Study of Ivacaftor in Cystic Fibrosis Subjects Aged 6 to 11 Years With the G551D Mutation&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">4</td><td class="on phases" data-content-name="cystic-fibrosis" data-intervention="Kalydeco" data-phase="other" data-placement="bottom_left" data-popup-id="popover-div" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01381289&quot;,&quot;title&quot;:&quot;VX-770 Expanded Access Program&quot;,&quot;phase&quot;:&quot;other&quot;}]">1</td><td class="on phases" data-content-name="cystic-fibrosis" data-intervention="Kalydeco" data-phase="all" data-placement="bottom_left" data-popup-id="popover-div" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01381289&quot;,&quot;title&quot;:&quot;VX-770 Expanded Access Program&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT00457821&quot;,&quot;title&quot;:&quot;Safety Study of Ivacaftor in Subjects With Cystic Fibrosis&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00953706&quot;,&quot;title&quot;:&quot;Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Homozygous for the F508del-CFTR Mutation&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01262352&quot;,&quot;title&quot;:&quot;Study of the Effect of Ivacaftor on Lung Clearance Index in Subjects With Cystic Fibrosis and the G551D Mutation&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01705145&quot;,&quot;title&quot;:&quot;Study of Ivacaftor in Cystic Fibrosis Subjects 2 Through 5 Years of Age With a CTFR Gating Mutation&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01707290&quot;,&quot;title&quot;:&quot;Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00909532&quot;,&quot;title&quot;:&quot;Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older With the G551D Mutation&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00909727&quot;,&quot;title&quot;:&quot;Study of Ivacaftor in Cystic Fibrosis Subjects Aged 6 to 11 Years With the G551D Mutation&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">8</td></td></tr>
<tr><td><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Ataluren</span><em class="manufacturer"></em><td data-content-name="cystic-fibrosis" data-intervention="Ataluren" data-phase="phase1" data-placement="bottom" data-popup-id="popover-div" data-source="null" data-trials="[]">0</td><td data-content-name="cystic-fibrosis" data-intervention="Ataluren" data-phase="phase2" data-placement="bottom" data-popup-id="popover-div" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="cystic-fibrosis" data-intervention="Ataluren" data-phase="phase3" data-placement="bottom" data-popup-id="popover-div" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01140451&quot;,&quot;title&quot;:&quot;Extension Study of Ataluren (PTC124) in Cystic Fibrosis&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00803205&quot;,&quot;title&quot;:&quot;Study of Ataluren (PTC124\u2122) in Cystic Fibrosis&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">2</td><td data-content-name="cystic-fibrosis" data-intervention="Ataluren" data-phase="other" data-placement="bottom_left" data-popup-id="popover-div" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="cystic-fibrosis" data-intervention="Ataluren" data-phase="all" data-placement="bottom_left" data-popup-id="popover-div" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01140451&quot;,&quot;title&quot;:&quot;Extension Study of Ataluren (PTC124) in Cystic Fibrosis&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00803205&quot;,&quot;title&quot;:&quot;Study of Ataluren (PTC124\u2122) in Cystic Fibrosis&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">2</td></td></tr>
<tr><td><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">VX-809 + ivacaftor</span><em class="manufacturer"></em><td class="on phases" data-content-name="cystic-fibrosis" data-intervention="VX-809 + ivacaftor" data-phase="phase1" data-placement="bottom" data-popup-id="popover-div" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01897233&quot;,&quot;title&quot;:&quot;Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects 6 to 11 Years of Age With F508del-CFTR Mutation&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td class="on phases" data-content-name="cystic-fibrosis" data-intervention="VX-809 + ivacaftor" data-phase="phase2" data-placement="bottom" data-popup-id="popover-div" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01225211&quot;,&quot;title&quot;:&quot;Study of VX-809 Alone and in Combination With VX-770 in Cystic Fibrosis (CF) Patients Homozygous or Heterozygous for the F508del-CFTR Mutation&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td class="on phases" data-content-name="cystic-fibrosis" data-intervention="VX-809 + ivacaftor" data-phase="phase3" data-placement="bottom" data-popup-id="popover-div" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01807923&quot;,&quot;title&quot;:&quot;A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation (TRAFFIC)&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01807949&quot;,&quot;title&quot;:&quot;A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation (TRANSPORT)&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">2</td><td data-content-name="cystic-fibrosis" data-intervention="VX-809 + ivacaftor" data-phase="other" data-placement="bottom_left" data-popup-id="popover-div" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="cystic-fibrosis" data-intervention="VX-809 + ivacaftor" data-phase="all" data-placement="bottom_left" data-popup-id="popover-div" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01897233&quot;,&quot;title&quot;:&quot;Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects 6 to 11 Years of Age With F508del-CFTR Mutation&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01225211&quot;,&quot;title&quot;:&quot;Study of VX-809 Alone and in Combination With VX-770 in Cystic Fibrosis (CF) Patients Homozygous or Heterozygous for the F508del-CFTR Mutation&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01807923&quot;,&quot;title&quot;:&quot;A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation (TRAFFIC)&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01807949&quot;,&quot;title&quot;:&quot;A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation (TRANSPORT)&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">4</td></td></tr>
<tr><td><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">VX-661 + ivacaftor</span><em class="manufacturer"></em><td data-content-name="cystic-fibrosis" data-intervention="VX-661 + ivacaftor" data-phase="phase1" data-placement="bottom" data-popup-id="popover-div" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="cystic-fibrosis" data-intervention="VX-661 + ivacaftor" data-phase="phase2" data-placement="bottom" data-popup-id="popover-div" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01531673&quot;,&quot;title&quot;:&quot;Study of VX-661 Alone and in Combination With Ivacaftor in Subjects Homozygous or Heterozygous to the F508del-Cystic Fibrosis Transmembrane Conductance Regulator(CFTR) Mutation&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02070744&quot;,&quot;title&quot;:&quot;Study to Evaluate Safety and Efficacy of VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">2</td><td data-content-name="cystic-fibrosis" data-intervention="VX-661 + ivacaftor" data-phase="phase3" data-placement="bottom" data-popup-id="popover-div" data-source="null" data-trials="[]">0</td><td data-content-name="cystic-fibrosis" data-intervention="VX-661 + ivacaftor" data-phase="other" data-placement="bottom_left" data-popup-id="popover-div" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="cystic-fibrosis" data-intervention="VX-661 + ivacaftor" data-phase="all" data-placement="bottom_left" data-popup-id="popover-div" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01531673&quot;,&quot;title&quot;:&quot;Study of VX-661 Alone and in Combination With Ivacaftor in Subjects Homozygous or Heterozygous to the F508del-Cystic Fibrosis Transmembrane Conductance Regulator(CFTR) Mutation&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02070744&quot;,&quot;title&quot;:&quot;Study to Evaluate Safety and Efficacy of VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">2</td></td></tr>
<tr><td><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">N6022</span><em class="manufacturer"></em><td class="on phases" data-content-name="cystic-fibrosis" data-intervention="N6022" data-phase="phase1" data-placement="bottom" data-popup-id="popover-div" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01746784&quot;,&quot;title&quot;:&quot;Safety and Pharmacokinetic Study of N6022 in Subjects With Cystic Fibrosis Homozygous for the F508del-CFTR Mutation&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="cystic-fibrosis" data-intervention="N6022" data-phase="phase2" data-placement="bottom" data-popup-id="popover-div" data-source="null" data-trials="[]">0</td><td data-content-name="cystic-fibrosis" data-intervention="N6022" data-phase="phase3" data-placement="bottom" data-popup-id="popover-div" data-source="null" data-trials="[]">0</td><td data-content-name="cystic-fibrosis" data-intervention="N6022" data-phase="other" data-placement="bottom_left" data-popup-id="popover-div" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="cystic-fibrosis" data-intervention="N6022" data-phase="all" data-placement="bottom_left" data-popup-id="popover-div" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01746784&quot;,&quot;title&quot;:&quot;Safety and Pharmacokinetic Study of N6022 in Subjects With Cystic Fibrosis Homozygous for the F508del-CFTR Mutation&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td></td></tr>
<tr class="subheader_0"><td colspan="6">Restore Airway Surface Liquid</td></tr><tr><td><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Hypertonic Saline</span><em class="manufacturer"></em><td data-content-name="cystic-fibrosis" data-intervention="Hypertonic Saline" data-phase="phase1" data-placement="bottom" data-popup-id="popover-div" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="cystic-fibrosis" data-intervention="Hypertonic Saline" data-phase="phase2" data-placement="bottom" data-popup-id="popover-div" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00934362&quot;,&quot;title&quot;:&quot;Effect of Lucinactant on Mucus Clearance in Cystic Fibrosis Lung Disease&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="cystic-fibrosis" data-intervention="Hypertonic Saline" data-phase="phase3" data-placement="bottom" data-popup-id="popover-div" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="cystic-fibrosis" data-intervention="Hypertonic Saline" data-phase="other" data-placement="bottom_left" data-popup-id="popover-div" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00546663&quot;,&quot;title&quot;:&quot;Tolerability of Inhaled Hypertonic Saline in Infants With Cystic Fibrosis&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT00709280&quot;,&quot;title&quot;:&quot;Infant Study of Inhaled Saline in Cystic Fibrosis&quot;,&quot;phase&quot;:&quot;other&quot;}]">2</td><td class="on phases" data-content-name="cystic-fibrosis" data-intervention="Hypertonic Saline" data-phase="all" data-placement="bottom_left" data-popup-id="popover-div" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00546663&quot;,&quot;title&quot;:&quot;Tolerability of Inhaled Hypertonic Saline in Infants With Cystic Fibrosis&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT00709280&quot;,&quot;title&quot;:&quot;Infant Study of Inhaled Saline in Cystic Fibrosis&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT00934362&quot;,&quot;title&quot;:&quot;Effect of Lucinactant on Mucus Clearance in Cystic Fibrosis Lung Disease&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">3</td></td></tr>
<tr><td><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Bronchitol</span><em class="manufacturer"></em><td data-content-name="cystic-fibrosis" data-intervention="Bronchitol" data-phase="phase1" data-placement="bottom" data-popup-id="popover-div" data-source="null" data-trials="[]">0</td><td data-content-name="cystic-fibrosis" data-intervention="Bronchitol" data-phase="phase2" data-placement="bottom" data-popup-id="popover-div" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="cystic-fibrosis" data-intervention="Bronchitol" data-phase="phase3" data-placement="bottom" data-popup-id="popover-div" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00630812&quot;,&quot;title&quot;:&quot;Long Term Administration of Inhaled Mannitol in Cystic Fibrosis&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td><td data-content-name="cystic-fibrosis" data-intervention="Bronchitol" data-phase="other" data-placement="bottom_left" data-popup-id="popover-div" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="cystic-fibrosis" data-intervention="Bronchitol" data-phase="all" data-placement="bottom_left" data-popup-id="popover-div" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00630812&quot;,&quot;title&quot;:&quot;Long Term Administration of Inhaled Mannitol in Cystic Fibrosis&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td></td></tr>
<tr class="subheader_0"><td colspan="6">Mucus Alteration</td></tr><tr><td><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Pulmozyme</span><em class="manufacturer"></em><td data-content-name="cystic-fibrosis" data-intervention="Pulmozyme" data-phase="phase1" data-placement="bottom" data-popup-id="popover-div" data-source="null" data-trials="[]">0</td><td data-content-name="cystic-fibrosis" data-intervention="Pulmozyme" data-phase="phase2" data-placement="bottom" data-popup-id="popover-div" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="cystic-fibrosis" data-intervention="Pulmozyme" data-phase="phase3" data-placement="bottom" data-popup-id="popover-div" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00630812&quot;,&quot;title&quot;:&quot;Long Term Administration of Inhaled Mannitol in Cystic Fibrosis&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td><td class="on phases" data-content-name="cystic-fibrosis" data-intervention="Pulmozyme" data-phase="other" data-placement="bottom_left" data-popup-id="popover-div" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01712334&quot;,&quot;title&quot;:&quot;A Study of the Comparable Efficacy and Safety of Pulmozyme (Dornase Alfa) Delivered by the eFlow Rapid Nebulizer System in Patients With Cystic Fibrosis&quot;,&quot;phase&quot;:&quot;other&quot;}]">1</td><td class="on phases" data-content-name="cystic-fibrosis" data-intervention="Pulmozyme" data-phase="all" data-placement="bottom_left" data-popup-id="popover-div" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01712334&quot;,&quot;title&quot;:&quot;A Study of the Comparable Efficacy and Safety of Pulmozyme (Dornase Alfa) Delivered by the eFlow Rapid Nebulizer System in Patients With Cystic Fibrosis&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT00630812&quot;,&quot;title&quot;:&quot;Long Term Administration of Inhaled Mannitol in Cystic Fibrosis&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">2</td></td></tr>
<tr><td><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Alpha 1 Anti-Trypsin</span><em class="manufacturer"></em><td data-content-name="cystic-fibrosis" data-intervention="Alpha 1 Anti-Trypsin" data-phase="phase1" data-placement="bottom" data-popup-id="popover-div" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="cystic-fibrosis" data-intervention="Alpha 1 Anti-Trypsin" data-phase="phase2" data-placement="bottom" data-popup-id="popover-div" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01684410&quot;,&quot;title&quot;:&quot;Safety and Tolerability Trial of Inhaled Alpha1-Proteinase Inhibitor (Human), Hydrophobic Chromatography Process (Alpha-1 HC) in Subjects With Cystic Fibrosis&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="cystic-fibrosis" data-intervention="Alpha 1 Anti-Trypsin" data-phase="phase3" data-placement="bottom" data-popup-id="popover-div" data-source="null" data-trials="[]">0</td><td data-content-name="cystic-fibrosis" data-intervention="Alpha 1 Anti-Trypsin" data-phase="other" data-placement="bottom_left" data-popup-id="popover-div" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="cystic-fibrosis" data-intervention="Alpha 1 Anti-Trypsin" data-phase="all" data-placement="bottom_left" data-popup-id="popover-div" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01684410&quot;,&quot;title&quot;:&quot;Safety and Tolerability Trial of Inhaled Alpha1-Proteinase Inhibitor (Human), Hydrophobic Chromatography Process (Alpha-1 HC) in Subjects With Cystic Fibrosis&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td></td></tr>
<tr><td><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">KB001-A</span><em class="manufacturer"></em><td data-content-name="cystic-fibrosis" data-intervention="KB001-A" data-phase="phase1" data-placement="bottom" data-popup-id="popover-div" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="cystic-fibrosis" data-intervention="KB001-A" data-phase="phase2" data-placement="bottom" data-popup-id="popover-div" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01695343&quot;,&quot;title&quot;:&quot;Study to Evaluate the Effect of KB001-A on Time-to-Need for Antibiotic Treatment&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00638365&quot;,&quot;title&quot;:&quot;Dose Escalation Study of KB001 in Cystic Fibrosis Patients Infected With Pseudomonas Aeruginosa&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">2</td><td data-content-name="cystic-fibrosis" data-intervention="KB001-A" data-phase="phase3" data-placement="bottom" data-popup-id="popover-div" data-source="null" data-trials="[]">0</td><td data-content-name="cystic-fibrosis" data-intervention="KB001-A" data-phase="other" data-placement="bottom_left" data-popup-id="popover-div" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="cystic-fibrosis" data-intervention="KB001-A" data-phase="all" data-placement="bottom_left" data-popup-id="popover-div" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01695343&quot;,&quot;title&quot;:&quot;Study to Evaluate the Effect of KB001-A on Time-to-Need for Antibiotic Treatment&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00638365&quot;,&quot;title&quot;:&quot;Dose Escalation Study of KB001 in Cystic Fibrosis Patients Infected With Pseudomonas Aeruginosa&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">2</td></td></tr>
<tr><td><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Sildenafil</span><em class="manufacturer"></em><td data-content-name="cystic-fibrosis" data-intervention="Sildenafil" data-phase="phase1" data-placement="bottom" data-popup-id="popover-div" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="cystic-fibrosis" data-intervention="Sildenafil" data-phase="phase2" data-placement="bottom" data-popup-id="popover-div" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00659529&quot;,&quot;title&quot;:&quot;Safety and Efficacy of Sildenafil in Cystic Fibrosis (CF) Lung Disease&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="cystic-fibrosis" data-intervention="Sildenafil" data-phase="phase3" data-placement="bottom" data-popup-id="popover-div" data-source="null" data-trials="[]">0</td><td data-content-name="cystic-fibrosis" data-intervention="Sildenafil" data-phase="other" data-placement="bottom_left" data-popup-id="popover-div" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="cystic-fibrosis" data-intervention="Sildenafil" data-phase="all" data-placement="bottom_left" data-popup-id="popover-div" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00659529&quot;,&quot;title&quot;:&quot;Safety and Efficacy of Sildenafil in Cystic Fibrosis (CF) Lung Disease&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td></td></tr>
<tr class="subheader_0"><td colspan="6">Anti-Infective</td></tr><tr><td><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Inhaled Tobramycin</span><em class="manufacturer"></em><td data-content-name="cystic-fibrosis" data-intervention="Inhaled Tobramycin" data-phase="phase1" data-placement="bottom" data-popup-id="popover-div" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="cystic-fibrosis" data-intervention="Inhaled Tobramycin" data-phase="phase2" data-placement="bottom" data-popup-id="popover-div" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00097773&quot;,&quot;title&quot;:&quot;Comparison of Two Treatment Regimens to Reduce PA Infection in Children With Cystic Fibrosis&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td class="on phases" data-content-name="cystic-fibrosis" data-intervention="Inhaled Tobramycin" data-phase="phase3" data-placement="bottom" data-popup-id="popover-div" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01082367&quot;,&quot;title&quot;:&quot;Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td><td data-content-name="cystic-fibrosis" data-intervention="Inhaled Tobramycin" data-phase="other" data-placement="bottom_left" data-popup-id="popover-div" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="cystic-fibrosis" data-intervention="Inhaled Tobramycin" data-phase="all" data-placement="bottom_left" data-popup-id="popover-div" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00097773&quot;,&quot;title&quot;:&quot;Comparison of Two Treatment Regimens to Reduce PA Infection in Children With Cystic Fibrosis&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01082367&quot;,&quot;title&quot;:&quot;Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">2</td></td></tr>
<tr><td><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Azithromycin</span><em class="manufacturer"></em><td data-content-name="cystic-fibrosis" data-intervention="Azithromycin" data-phase="phase1" data-placement="bottom" data-popup-id="popover-div" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="cystic-fibrosis" data-intervention="Azithromycin" data-phase="phase2" data-placement="bottom" data-popup-id="popover-div" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00298922&quot;,&quot;title&quot;:&quot;Azithromycin in Patients With CF, Infected With Burkholderia Cepacia Complex&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td class="on phases" data-content-name="cystic-fibrosis" data-intervention="Azithromycin" data-phase="phase3" data-placement="bottom" data-popup-id="popover-div" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01270074&quot;,&quot;title&quot;:&quot;Prevention of Bronchiectasis in Infants With Cystic Fibrosis&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02054156&quot;,&quot;title&quot;:&quot;OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">2</td><td class="on phases" data-content-name="cystic-fibrosis" data-intervention="Azithromycin" data-phase="other" data-placement="bottom_left" data-popup-id="popover-div" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00431964&quot;,&quot;title&quot;:&quot;Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Who Are Not Infected With P. Aeruginosa&quot;,&quot;phase&quot;:&quot;other&quot;}]">1</td><td class="on phases" data-content-name="cystic-fibrosis" data-intervention="Azithromycin" data-phase="all" data-placement="bottom_left" data-popup-id="popover-div" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00431964&quot;,&quot;title&quot;:&quot;Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Who Are Not Infected With P. Aeruginosa&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT00298922&quot;,&quot;title&quot;:&quot;Azithromycin in Patients With CF, Infected With Burkholderia Cepacia Complex&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01270074&quot;,&quot;title&quot;:&quot;Prevention of Bronchiectasis in Infants With Cystic Fibrosis&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02054156&quot;,&quot;title&quot;:&quot;OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">4</td></td></tr>
<tr><td><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Cayston®</span><em class="manufacturer"></em><td data-content-name="cystic-fibrosis" data-intervention="Cayston®" data-phase="phase1" data-placement="bottom" data-popup-id="popover-div" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="cystic-fibrosis" data-intervention="Cayston®" data-phase="phase2" data-placement="bottom" data-popup-id="popover-div" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01375049&quot;,&quot;title&quot;:&quot;Aztreonam Lysine for Pseudomonas Infection Eradication Study&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td class="on phases" data-content-name="cystic-fibrosis" data-intervention="Cayston®" data-phase="phase3" data-placement="bottom" data-popup-id="popover-div" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01641822&quot;,&quot;title&quot;:&quot;Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00104520&quot;,&quot;title&quot;:&quot;Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00128492&quot;,&quot;title&quot;:&quot;Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis (CF) Patients With Pseudomonas Aeruginosa (PA)&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00112359&quot;,&quot;title&quot;:&quot;International Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00757237&quot;,&quot;title&quot;:&quot;Aztreonam for Inhalation Solution vs Tobramycin Inhalation Solution in Patients With Cystic Fibrosis \u0026 Pseudomonas Aeruginosa&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01059565&quot;,&quot;title&quot;:&quot;Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis and Chronic Burkholderia Species Infection&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01404234&quot;,&quot;title&quot;:&quot;Safety of AZLI in Children With Cystic Fibrosis (CF) and Chronic Pseudomonas Aeruginosa in the Lower Airways&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">7</td><td class="on phases" data-content-name="cystic-fibrosis" data-intervention="Cayston®" data-phase="other" data-placement="bottom_left" data-popup-id="popover-div" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00499720&quot;,&quot;title&quot;:&quot;Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Airway Infection&quot;,&quot;phase&quot;:&quot;other&quot;}]">1</td><td class="on phases" data-content-name="cystic-fibrosis" data-intervention="Cayston®" data-phase="all" data-placement="bottom_left" data-popup-id="popover-div" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00499720&quot;,&quot;title&quot;:&quot;Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Airway Infection&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01375049&quot;,&quot;title&quot;:&quot;Aztreonam Lysine for Pseudomonas Infection Eradication Study&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01641822&quot;,&quot;title&quot;:&quot;Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00104520&quot;,&quot;title&quot;:&quot;Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00128492&quot;,&quot;title&quot;:&quot;Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis (CF) Patients With Pseudomonas Aeruginosa (PA)&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00112359&quot;,&quot;title&quot;:&quot;International Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT00757237&quot;,&quot;title&quot;:&quot;Aztreonam for Inhalation Solution vs Tobramycin Inhalation Solution in Patients With Cystic Fibrosis \u0026 Pseudomonas Aeruginosa&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01059565&quot;,&quot;title&quot;:&quot;Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis and Chronic Burkholderia Species Infection&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01404234&quot;,&quot;title&quot;:&quot;Safety of AZLI in Children With Cystic Fibrosis (CF) and Chronic Pseudomonas Aeruginosa in the Lower Airways&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">9</td></td></tr>
<tr><td><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">TIP</span><em class="manufacturer"></em><td data-content-name="cystic-fibrosis" data-intervention="TIP" data-phase="phase1" data-placement="bottom" data-popup-id="popover-div" data-source="null" data-trials="[]">0</td><td data-content-name="cystic-fibrosis" data-intervention="TIP" data-phase="phase2" data-placement="bottom" data-popup-id="popover-div" data-source="null" data-trials="[]">0</td><td data-content-name="cystic-fibrosis" data-intervention="TIP" data-phase="phase3" data-placement="bottom" data-popup-id="popover-div" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="cystic-fibrosis" data-intervention="TIP" data-phase="other" data-placement="bottom_left" data-popup-id="popover-div" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02015663&quot;,&quot;title&quot;:&quot;Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01519661&quot;,&quot;title&quot;:&quot;Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01775137&quot;,&quot;title&quot;:&quot;Ext. Long-term Safety Study in CF Patients: Single Arm TIP&quot;,&quot;phase&quot;:&quot;other&quot;}]">3</td><td class="on phases" data-content-name="cystic-fibrosis" data-intervention="TIP" data-phase="all" data-placement="bottom_left" data-popup-id="popover-div" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02015663&quot;,&quot;title&quot;:&quot;Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01519661&quot;,&quot;title&quot;:&quot;Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01775137&quot;,&quot;title&quot;:&quot;Ext. Long-term Safety Study in CF Patients: Single Arm TIP&quot;,&quot;phase&quot;:&quot;other&quot;}]">3</td></td></tr>
<tr><td><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Levofloxacin</span><em class="manufacturer"></em><td class="on phases" data-content-name="cystic-fibrosis" data-intervention="Levofloxacin" data-phase="phase1" data-placement="bottom" data-popup-id="popover-div" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00840333&quot;,&quot;title&quot;:&quot;Safety, Tolerability and Pharmacokinetics of MP-376 Administered for 14 Days to Stable Pediatric (CF) Patients&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td class="on phases" data-content-name="cystic-fibrosis" data-intervention="Levofloxacin" data-phase="phase2" data-placement="bottom" data-popup-id="popover-div" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00677365&quot;,&quot;title&quot;:&quot;Safety, Tolerability and Efficacy of MP-376 Given for 28 Days to Cystic Fibrosis (CF) Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td class="on phases" data-content-name="cystic-fibrosis" data-intervention="Levofloxacin" data-phase="phase3" data-placement="bottom" data-popup-id="popover-div" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01180634&quot;,&quot;title&quot;:&quot;MP-376 (Aeroquin\u2122, Levofloxacin for Inhalation) in Patients With Cystic Fibrosis&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01270347&quot;,&quot;title&quot;:&quot;Trial of Aeroquin Versus Tobramycin Inhalation Solution (TIS) in Cystic Fibrosis (CF) Patients&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">2</td><td data-content-name="cystic-fibrosis" data-intervention="Levofloxacin" data-phase="other" data-placement="bottom_left" data-popup-id="popover-div" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="cystic-fibrosis" data-intervention="Levofloxacin" data-phase="all" data-placement="bottom_left" data-popup-id="popover-div" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00840333&quot;,&quot;title&quot;:&quot;Safety, Tolerability and Pharmacokinetics of MP-376 Administered for 14 Days to Stable Pediatric (CF) Patients&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT00677365&quot;,&quot;title&quot;:&quot;Safety, Tolerability and Efficacy of MP-376 Given for 28 Days to Cystic Fibrosis (CF) Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01180634&quot;,&quot;title&quot;:&quot;MP-376 (Aeroquin\u2122, Levofloxacin for Inhalation) in Patients With Cystic Fibrosis&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01270347&quot;,&quot;title&quot;:&quot;Trial of Aeroquin Versus Tobramycin Inhalation Solution (TIS) in Cystic Fibrosis (CF) Patients&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">4</td></td></tr>
<tr><td><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Arikace™</span><em class="manufacturer"></em><td data-content-name="cystic-fibrosis" data-intervention="Arikace™" data-phase="phase1" data-placement="bottom" data-popup-id="popover-div" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="cystic-fibrosis" data-intervention="Arikace™" data-phase="phase2" data-placement="bottom" data-popup-id="popover-div" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01315236&quot;,&quot;title&quot;:&quot;Arikace\u00ae for Nontuberculous Mycobacteria&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00558844&quot;,&quot;title&quot;:&quot;Multidose Safety and Tolerability Study of (Arikace\u2122) for Inhalation In Cystic Fibrosis Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">2</td><td class="on phases" data-content-name="cystic-fibrosis" data-intervention="Arikace™" data-phase="phase3" data-placement="bottom" data-popup-id="popover-div" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01315678&quot;,&quot;title&quot;:&quot;Study to Evaluate Arikace\u2122 in CF Patients With Chronic Pseudomonas Aeruginosa Infections&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01315691&quot;,&quot;title&quot;:&quot;Study to Evaluate Arikace\u2122 in CF Patients With Chronic Infection Due to Pseudomonas Aeruginosa&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01316276&quot;,&quot;title&quot;:&quot;Extension Study of Arikace\u2122 in CF Patients With Chronic Pseudomonas Aeruginosa Infection&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">3</td><td data-content-name="cystic-fibrosis" data-intervention="Arikace™" data-phase="other" data-placement="bottom_left" data-popup-id="popover-div" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="cystic-fibrosis" data-intervention="Arikace™" data-phase="all" data-placement="bottom_left" data-popup-id="popover-div" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01315236&quot;,&quot;title&quot;:&quot;Arikace\u00ae for Nontuberculous Mycobacteria&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00558844&quot;,&quot;title&quot;:&quot;Multidose Safety and Tolerability Study of (Arikace\u2122) for Inhalation In Cystic Fibrosis Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01315678&quot;,&quot;title&quot;:&quot;Study to Evaluate Arikace\u2122 in CF Patients With Chronic Pseudomonas Aeruginosa Infections&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01315691&quot;,&quot;title&quot;:&quot;Study to Evaluate Arikace\u2122 in CF Patients With Chronic Infection Due to Pseudomonas Aeruginosa&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01316276&quot;,&quot;title&quot;:&quot;Extension Study of Arikace\u2122 in CF Patients With Chronic Pseudomonas Aeruginosa Infection&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">5</td></td></tr>
<tr><td><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">AeroVanc™</span><em class="manufacturer"></em><td data-content-name="cystic-fibrosis" data-intervention="AeroVanc™" data-phase="phase1" data-placement="bottom" data-popup-id="popover-div" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="cystic-fibrosis" data-intervention="AeroVanc™" data-phase="phase2" data-placement="bottom" data-popup-id="popover-div" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01746095&quot;,&quot;title&quot;:&quot;Efficacy and Safety Study of AeroVanc for the Treatment of Persistent MRSA Lung Infection in Cystic Fibrosis Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="cystic-fibrosis" data-intervention="AeroVanc™" data-phase="phase3" data-placement="bottom" data-popup-id="popover-div" data-source="null" data-trials="[]">0</td><td data-content-name="cystic-fibrosis" data-intervention="AeroVanc™" data-phase="other" data-placement="bottom_left" data-popup-id="popover-div" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="cystic-fibrosis" data-intervention="AeroVanc™" data-phase="all" data-placement="bottom_left" data-popup-id="popover-div" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01746095&quot;,&quot;title&quot;:&quot;Efficacy and Safety Study of AeroVanc for the Treatment of Persistent MRSA Lung Infection in Cystic Fibrosis Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td></td></tr>
<tr><td><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Nutrition</span><em class="manufacturer"></em><td data-content-name="cystic-fibrosis" data-intervention="Nutrition" data-phase="phase1" data-placement="bottom" data-popup-id="popover-div" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="cystic-fibrosis" data-intervention="Nutrition" data-phase="phase2" data-placement="bottom" data-popup-id="popover-div" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01859390&quot;,&quot;title&quot;:&quot;Effects of an Antioxidant-Enriched Multivitamin Supplement on Inflammation and Oxidative Stress in Cystic Fibrosis&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td><td data-content-name="cystic-fibrosis" data-intervention="Nutrition" data-phase="phase3" data-placement="bottom" data-popup-id="popover-div" data-source="null" data-trials="[]">0</td><td data-content-name="cystic-fibrosis" data-intervention="Nutrition" data-phase="other" data-placement="bottom_left" data-popup-id="popover-div" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="cystic-fibrosis" data-intervention="Nutrition" data-phase="all" data-placement="bottom_left" data-popup-id="popover-div" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01859390&quot;,&quot;title&quot;:&quot;Effects of an Antioxidant-Enriched Multivitamin Supplement on Inflammation and Oxidative Stress in Cystic Fibrosis&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">1</td></td></tr>
<tr><td><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Liprotamase</span><em class="manufacturer"></em><td data-content-name="cystic-fibrosis" data-intervention="Liprotamase" data-phase="phase1" data-placement="bottom" data-popup-id="popover-div" data-source="null" data-trials="[]">0</td><td data-content-name="cystic-fibrosis" data-intervention="Liprotamase" data-phase="phase2" data-placement="bottom" data-popup-id="popover-div" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="cystic-fibrosis" data-intervention="Liprotamase" data-phase="phase3" data-placement="bottom" data-popup-id="popover-div" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00449878&quot;,&quot;title&quot;:&quot;ALTU-135 Efficacy Trial in Patients With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td><td data-content-name="cystic-fibrosis" data-intervention="Liprotamase" data-phase="other" data-placement="bottom_left" data-popup-id="popover-div" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="cystic-fibrosis" data-intervention="Liprotamase" data-phase="all" data-placement="bottom_left" data-popup-id="popover-div" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00449878&quot;,&quot;title&quot;:&quot;ALTU-135 Efficacy Trial in Patients With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td></td></tr>
</table>
<p>
*
<em>Phase 4 or compassionate care study</em>
<br>
**
<em>Only ongoing studies are included (recruiting, pending recruitment or active, but not yet recruiting)</em>
</p>
<p>
<a href="../contact-subject=The++trial+table+is+missing+a+trial.html" rel="nofollow">Are we missing a trial?</a>
</p>
<div class='popover-div' id='popover-div'></div>

</div>
</div>
</div>

</div>
<div class='span3 sidebar no-padding-or-margin'>

<div class='widget '>
<div class='community-promo'>
<h1><a href="../communities/cystic-fibrosis.html">Cystic Fibrosis at Smart Patients</a></h1>
<p>
The Smart Patients Cystic Fibrosis community is an online discussion forum where members
share advice and support with other patients and caregivers.
</p>
</div>

<hr>
</div>
<div class='widget '>
<div class='invitation-widget'>
<h2>Join the conversation!</h2>
<form accept-charset="UTF-8" action="/users" class="signup form-inline" id="new_user" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="anHdzK0RV47A1fm+Cc5YWchDmz7Dd1CW3v8C5VSfjds=" /></div><div class='join-button'>
<input class="btn btn-primary join-btn" name="commit" type="submit" value="Join Now" />
</div>
<div class="control-group required"><div class="controls"><input class="email required ezpz" id="invitation_email" name="user[email]" placeholder="Enter your email address" required="required" size="30" type="text" /></div></div>
<div class="notice"><p>If you're not a patient or caregiver, <a href="../contact-subject=Joining+Smart+Patients.html">click here</a>.</p></div>
<div class='notice'>
<p class='already-a-member'>Already a member? <a href="../signin.html">Sign in</a>.</p>
</div>
<input id="community" name="community" type="hidden" value="cystic-fibrosis" />
<input id="partner" name="partner" type="hidden" value="" />
<input id="tags" name="tags" type="hidden" value="cystic fibrosis" />
<input id="return_url" name="return_url" type="hidden" value="/cystic-fibrosis/trials" />
<div class='controls request-button'>
<input class="btn btn-primary join-btn" name="commit" type="submit" value="Join Now" />
</div>
<div class='clearfix'></div>
</form>
</div>


<hr>
</div>
<div class='widget '>
<p>In cystic fibrosis, the CFTR protein (cystic fibrosis conductance trans-membrane regulator) is defective, inactive, or present in smaller amounts than normal. This causes thick mucus to clog the airways in the lungs.</p>
<figure>
<img alt="CFTR mutations" height="481" src="../assets/content_pages/cftr_mutations-1-724f35b7da845a378529e6586c180f31.jpg" width="199" />
<figcaption>Image from <a href="http://www.hopkinscf.org/what-is-cf/basic-science/cftr/mutations/" target="_blank">Johns Hopkins Cystic Fibrosis Center</a></figcaption>
</figure>

<hr>
</div>


</div>
</div>
</div>
</div>
</div>
<div class='footer_background_container'>
<div class='footer_background'></div>
</div>
<div id='fat_footer'>
<div class='container'>
<footer class='row'>
<ul>
<li class='title'>
Links
</li>
<li>
<a href='../signin.html' title='Smart Patients - Home'>Conversations</a>
</li>
<li>
<a href='../stories.html' title='Stories'>Stories</a>
</li>
<li>
<a href='../quotes.html' title='Quotes recommended by members of the Smart Patients community.'>Quotes</a>
</li>
<li>
<a href='../trials.html' title='Search for clinical trials'>Clinical Trials</a>
</li>
</ul>
<ul>
<li class='title'>
Resources
</li>
<li>
<a href='../tutorial.html' title='Tutorial'>Tutorial</a>
</li>
<li>
<a href='../glossary.html' title='Tutorial'>Glossary</a>
</li>
<li>
<a href='../faq.html' title='Frequently asked questions'>FAQ</a>
</li>
</ul>
<ul>
<li class='title'>
Company
</li>
<li>
<a href='../about.html' title='About'>About</a>
</li>
<li>
<a href='../terms.html' title='Terms of Agreement'>Terms</a>
</li>
<li>
<a href='../privacy.html' title='Privacy Statement'>Privacy</a>
</li>
<li>
<a href='../contact.html' title='Contact Us'>Contact Us</a>
</li>
</ul>
<ul>
<li class='title'>
Social
</li>
<li>
<a href='../voices.html' title='Community Voices'>
<img alt="Icon_community_voices" src="../assets/icon_community_voices-51b928126bf735b2f04e9c969184afe3.png" />
Community Voices
</a>
</li>
<li>
<a href='../blog/index.html' title='Smart Patients Blog'>
<img alt="Icon_rss" src="../assets/icon_rss-16f5922fc759195730036b4454ef43a9.png" />
Smart Patients Blog
</a>
</li>
<li>
<a href='https://twitter.com/smart_patients' target='_blank' title='Twitter'>
<img alt="Icon_twitter" src="../assets/icon_twitter-5f7dbcc5d175199272b25b76fdda7dcd.png" />
Twitter
</a>
</li>
<li>
<a href='https://www.facebook.com/pages/Smart-Patients/393175704082838' target='_blank' title='Facebook'>
<img alt="Icon_facebook" src="../assets/icon_facebook-bb0ca36aa4757152d61004e0595d2e50.png" />
Facebook
</a>
</li>
</ul>
</footer>
<div class='copyright'>&copy;2015 Smart Patients, Inc., all rights reserved
</div>
<div class='creative_commons'>
<a href="../creative_commons.html">some icons</a>
are licensed under the Creative Commons license.
</div>
</div>
</div>

<script>
  var _gaq = _gaq || [];
  _gaq.push(['_setAccount', "UA-33347034-1"]);
  _gaq.push(['_setDomainName', 'smartpatients.com']);
  _gaq.push(['_trackPageview']);
  
  _gaq.push(['_setCustomVar',
    1,
    'logged_in',
    "false",
    2 // session-level
  ]);
  (function() {
    var ga = document.createElement('script'); ga.type = 'text/javascript'; ga.async = true;
    ga.src = ('https:' == document.location.protocol ? 'https://ssl' : 'http://www') + '.google-analytics.com/ga.js';
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(ga, s);
  })();
</script>


<script src="../assets/application-6488ad0d66b77f64bcc10cde7b8e3212.js" type="text/javascript"></script>
<script src="../assets/jquery.hoverIntent.minified-3948fb0a36bb799e79553266985a1b22.js" type="text/javascript"></script>
<script src="../assets/jquery.validate.min-639617c1797dd4f18f2e40348e222928.js" type="text/javascript"></script>
<script src="../assets/jquery.cookie-108e498e814a1dbb62f1c6a88c61db48.js" type="text/javascript"></script>
<!--[if lt IE 10]>  <![endif]-->
<script src="../assets/jquery.placeholder.min-635ef1b648831ce3225097bb831210ca.js" type="text/javascript"></script>
<script>
  (function() {
    var root;
  
    root = typeof exports !== "undefined" && exports !== null ? exports : this;
  
    if ($('.wmd-input').length === 1) {
      root.converter = Markdown.getSanitizingConverter();
      root.converter.hooks.chain("preConversion", function(text) {
        text = text.replace(/^https?:\/\/[a-z0-9\.:]+(\/forums\/1-conversations\/topics\/[0-9]+-.*$)/mgi, "[Title of linked conversation will appear here]($1)");
        text = text.replace(/^(NCT[0-9]{8})$/mgi, "[Title for '$1' will appear here](/trials/$1)");
        text = text.replace(/:-\)/g, '☺');
        text = text.replace(/:-\(/g, '☹');
        text = text.replace(/:flower:/g, '⚘');
        text = text.replace(/:heart:/g, '❤');
        text = text.replace(/:star:/g, '★');
        text = text.replace(/:rose:/g, '❀');
        text = text.replace(/:music:/g, '♫');
        return text.replace(/(^|[\s\(])(NCT[0-9]{8})($|[\s\)])/gi, "$1[$2](/trials/$2)$3");
      });
      root.editor = new Markdown.Editor(converter);
      root.editor.run();
    }
  
  }).call(this);
</script>




</body>
</html>
